Table 4.
Effect of presence of aGVHD (grades II–IV) compared to those without aGVHD at same time point, based on propensity-weighteda models for quality of life patient-reported outcomes after adjusting for baseline values and cohort.
| Assessment | Estimate (95% CI) | P value |
|---|---|---|
| Depression | 3.13 (−1.77, 8.04) | 0.19 |
| Anxiety | 0.94 (−1.20, 3.08) | 0.35 |
| Fatigue, intensity | 0.37 (−0.63, 1.36) | 0.43 |
| Fatigue, duration | 2.56 (0.36, 4.76) | 0.03 |
| Fatigue, interference | 1.01 (−0.08, 2.10) | 0.07 |
| Pain, intensity | 0.25 (−0.66, 1.17) | 0.55 |
| Pain, interference | 0.12 (−0.95, 1.19) | 0.81 |
| Sleep | −0.06 (−1.98, 1.87) | 0.95 |
aPropensity scores were obtained using a logistic regression model with age, sex, BMI, CMV status, conditioning regimen, and donor type as predictors of study group.